


# SCIENTIFIC REPORTS



OPEN

## Deletion of *EP4* in *S100a4*-lineage cells reduces scar tissue formation during early but not later stages of tendon healing

Jessica E. Ackerman<sup>1</sup>, Katherine T. Best<sup>1</sup>, Regis J. O'Keefe<sup>2</sup> & Alayna E. Loisel<sup>1</sup> 


Tendon injuries heal via scar tissue rather than regeneration. This healing response forms adhesions between the flexor tendons in the hand and surrounding tissues, resulting in impaired range of motion and hand function. Mechanistically, inflammation has been strongly linked to adhesion formation, and Prostaglandin E2 (PGE2) is associated with both adhesion formation and tendinopathy. In the present study we tested the hypothesis that deletion of the PGE2 receptor *EP4* in *S100a4*-lineage cells would decrease adhesion formation. *S100a4*-Cre; *EP4*<sup>flox/flox</sup> (*EP4cKO*<sup>*S100a4*</sup>) repairs healed with improved gliding function at day 14, followed by impaired gliding at day 28, relative to wild type. Interestingly, *EP4cKO*<sup>*S100a4*</sup> resulted in only transient deletion of *EP4*, suggesting up-regulation of *EP4* in an alternative cell population in these mice. Loss of *EP4* in *Scleraxis*-lineage cells did not alter gliding function, suggesting that *Scx*-lineage cells are not the predominant *EP4* expressing population. In contrast, a dramatic increase in  $\alpha$ -SMA<sup>+</sup>, *EP4*<sup>+</sup> double-positive cells were observed in *EP4cKO*<sup>*S100a4*</sup> suggesting that *EP4cKO*<sup>*S100a4*</sup> repairs heal with increased infiltration of *EP4* expressing  $\alpha$ -SMA myofibroblasts, identifying a potential mechanism of late up-regulation of *EP4* and impaired gliding function in *EP4cKO*<sup>*S100a4*</sup> tendon repairs.

Tendons are dense connective tissues composed primarily of a highly organized type I collagen extracellular matrix (ECM). The hierarchical structure of the collagen ECM allows tendons to transmit large forces between muscle and bone, facilitating movement of nearly the entire body. Acute traumatic injuries to the tendon are quite common due in part to the superficial anatomic location of many tendons. Following injury, tendons generally heal with a scar tissue response rather than regeneration of native tendon. This fibrotic healing response is particularly problematic in the hands, as excursion of the flexor tendons within the synovial sheath is restricted by both increased tissue bulk and the formation of adhesions between the tendon and surrounding tissues. Currently, treatment to restore digit range of motion (ROM) after injury is limited to surgical 'tenolysis' procedures<sup>1</sup>, however this intervention provides only a temporary return to function. Thus, a better understanding of the fundamental cellular and molecular components of fibrotic healing are needed in order to inform development of future therapeutic interventions to improve tendon healing.

Tendon healing is composed of three over-lapping phases of healing including inflammation, proliferative/matrix deposition, and the remodeling phase. Several studies have demonstrated that anti-inflammatory treatment, particularly Cox-2 inhibition, effectively reduces adhesion formation<sup>2,3</sup>, however, mechanical properties can also be compromised with this approach<sup>2</sup>. Therefore, recent studies have focused on downstream signaling of Cox-2 as potential therapeutic targets. Cox-2 catalyzes the conversion of Arachidonic Acid to Prostaglandins, including PGE2, which is associated with tendinopathy and involved in tendon repair<sup>4-8</sup>. Moreover, *EP4* has been identified as the specific receptor through which degenerative tendinopathic changes of PGE2 are mediated<sup>9</sup>. We have previously demonstrated that systemic *EP4* antagonism increased adhesion formation, relative to vehicle treated repairs<sup>10</sup>, however the specific function of *EP4* is dependent on cell type<sup>11,12</sup>. Therefore, in the present study we have focused on the effects of cell-type specific *EP4* deletion on tendon healing.

<sup>1</sup>Center for Musculoskeletal Research, University of Rochester, Rochester, New York, United States of America.

<sup>2</sup>Department of Orthopedic Surgery, Washington University School of Medicine, St. Louis, Missouri, United States of America. Correspondence and requests for materials should be addressed to A.E.L. (email: [Alayna\\_Loiselle@urmc.rochester.edu](mailto:Alayna_Loiselle@urmc.rochester.edu))




**Figure 1.** *S100a4*-Cre effectively targets tendon. To demonstrate that *S100a4*-Cre effectively targets recombination in the tendon we examined healing in the double reporter nT/nG with *S100a4*-Cre<sup>+</sup> cells expressing GFP, and *S100a4*-Cre<sup>-</sup> cells expressing Td Tomato Red. *S100a4*-Cre results in recombination in both the (A) un-injured and (B & C) repaired tendon at days 7 (B & B') and 14 (C & C') post-surgery. Tendon tissue is outlined in white, (\*) indicate auto-fluorescent sutures at the repair site. Scale bars (A,B',C) represent 100 microns, and (B & C) 200 microns. (D) Quantification of the proportion of nGFP<sup>+</sup> (*S100a4*-Cre<sup>+</sup>) cells in the un-injured tendon and at 7 and 14 days post-repair. (\*\*\*) Indicates p < 0.001 vs. un-injured.


In the present study we utilized *S100a4*-Cre; *EP4*<sup>fllox/fllox</sup> (*EP4*cKO<sup>*S100a4*</sup>) mice to test the hypothesis that conditional deletion of *EP4* in *S100a4*-lineage cells would reduce adhesion formation while maintaining mechanical properties, relative to wildtype (WT) littermates. *S100a4* (S100 Calcium Binding Protein A4) is a member of the EF-hand Ca<sup>2+</sup>-binding proteins, and is associated with fibrosis in several tissues<sup>13–16</sup>. Given the fibrotic nature of scar-mediated tendon healing, we determined the feasibility of using *S100a4*-Cre as an efficient means to target the tendon during healing, and demonstrate recombination in both the un-injured tendon, and at the tendon repair site. We show that flexor tendon repairs from *EP4*cKO<sup>*S100a4*</sup> have only a transient, early inhibition of *EP4* expression, concomitant with early reductions in adhesion formation. However, during later healing *EP4* expression is increased in *EP4*cKO<sup>*S100a4*</sup> repairs relative to WT, suggesting an alternative cell population up-regulates *EP4* in these mice. We then show that loss of *EP4* in *Scleraxis*-lineage cells does not alter adhesion formation, while *EP4*cKO<sup>*S100a4*</sup> repairs have an increase in the myofibroblast marker  $\alpha$ -SMA, suggesting a potential mechanism of increased adhesion formation that occurs during later healing in *EP4*cKO<sup>*S100a4*</sup> mice.

## Results

***S100a4*-lineage cells are found in both native tendon and the granulation tissue.** To determine the expression pattern of *S100a4*-lineage cells using *S100a4*-Cre, and thus the potential localization of *EP4* conditional deletion, the *ROSA*<sup>nT/nG</sup> dual reporter was used. GFP-expressing (*S100a4*-Cre<sup>+</sup>) cells were observed in 40.5% of resident tenocytes in the absence of injury (Fig. 1A,D). At day 7 post-surgery abundant GFP<sup>+</sup>, *S100a4*-Cre<sup>+</sup> cells were observed throughout the native tendon and within the highly cellular bridging granulation tissue (Fig. 1B and B', Supplemental Fig. 1), with 79.9% of cells in the scar tissue being nGFP<sup>+</sup> (*S100a4*<sup>+</sup>) (p < 0.001 vs. un-injured)(Fig. 1D). At day 14 post-repair a few GFP<sup>+</sup>, *S100a4*-Cre<sup>+</sup> cells were observed in the ends of the native tendon, however, abundant GFP<sup>+</sup>, *S100a4*-Cre<sup>+</sup> cells were present in the granulation tissue that bridges the injury site (Fig. 1C and C'), with 74.7% of cells in the scar tissue being nGFP<sup>+</sup> (*S100a4*<sup>+</sup>) (p < 0.001 vs un-injured) (Fig. 1D).




**Figure 2.** EP4cKO<sup>S100a4</sup> does not alter gliding function or mechanical properties of un-injured tendons. No changes in (A) Max load at failure, (B) MTP Flexion Angle, or (C) Gliding Resistance were observed between un-injured tendons from WT and EP4cKO<sup>S100a4</sup> flexor tendons. For tensile testing, all un-injured tendons failed at the tendon mid-substance.



**Figure 3.** EP4cKO<sup>S100a4</sup> significantly decreases *EP4* expression during early healing. mRNA was isolated from EP4cKO<sup>S100a4</sup> and WT tendon repairs between 7–28 days post-surgery. Relative *EP4* expression was significantly decreased in EP4cKO<sup>S100a4</sup> relative to WT at day 7, and was significantly increased on days 14 and 21 post-surgery. Expression was normalized to the internal control  $\beta$ -actin. (\*) Indicates  $p < 0.05$ .

**EP4cKO<sup>S100a4</sup> Does not alter mechanical properties of un-injured tendons.** To ensure that EP4cKO<sup>S100a4</sup> did not impair baseline mechanical properties and gliding function of the FDL, un-injured tendons were used. No change in Max load at failure (WT:  $7.33 \pm 0.35$ ; EP4cKO<sup>S100a4</sup>:  $7.89 \pm 0.67$   $p = 0.46$ ) (Fig. 2A), stiffness or energy to Max (data not shown) were observed between un-injured EP4cKO<sup>S100a4</sup> and WT tendons. Additionally, no change in MTP flexion angle (WT:  $51.98 \pm 1.75$ ; EP4cKO<sup>S100a4</sup>:  $51.78 \pm 3.95$ ,  $p = 0.96$ ) (Fig. 2B) and Gliding Resistance (WT:  $9.63 \pm 0.95$ ; EP4cKO<sup>S100a4</sup>:  $11.09 \pm 2.11$ ,  $p = 0.53$ ) were observed between genotypes (Fig. 2C).

**EP4 expression is decreased during early but not late healing in EP4cKO<sup>S100a4</sup> tendon repairs.** To determine the temporal effects of EP4cKO<sup>S100a4</sup> on *EP4* expression during healing, mRNA was isolated from WT and EP4cKO<sup>S100a4</sup> repairs between 7 and 28 days post-repair. Peak *EP4* expression was observed in WT repairs at day 7 post-repair, consistent with previous studies<sup>10</sup>, followed by a significant reduction in *EP4* expression at 14, 21 and 28 days, relative to day 7. A significant 63.9% reduction in *EP4* expression was observed in EP4cKO<sup>S100a4</sup> repairs relative to WT ( $p = 0.0135$ , Fig. 3) at day 7, identifying efficient reduction in *EP4* expression at this time. In contrast, *EP4* expression was significantly increased in EP4cKO<sup>S100a4</sup> repairs at days 14 and 21, relative to time-point matched WT repairs. No change in *EP4* expression was observed between WT and EP4cKO<sup>S100a4</sup> repairs at day 28 (Fig. 3).



**Figure 4.** EP4cKO<sup>S100a4</sup> significantly improves early gliding function without compromising mechanical properties during flexor tendon healing. (A) MTP Flexion Angle, and (B) Gliding Resistance were measured in WT and EP4cKO<sup>S100a4</sup> flexor tendons between 10–28 days post-surgery. (C) Max load at failure, and (D) Stiffness were assessed between 14–28 days post-surgery. For tensile testing, all repaired tendons failed at the suture site. (\*) Indicates  $p < 0.05$  between WT and EP4cKO<sup>S100a4</sup> at the same time-point.

#### EP4cKO<sup>S100a4</sup> flexor tendon repairs have an early, transient improvement in gliding function.


No differences in MTP flexion angle were observed at day 10 post-repair between WT and EP4cKO<sup>S100a4</sup> mice. However, by day 14 a significant 71% increase in MTP flexion angle was observed in EP4cKO<sup>S100a4</sup> repairs (WT:  $14.53 \pm 1.74$ ; EP4cKO<sup>S100a4</sup>:  $28.55 \pm 5.44$ ,  $p = 0.03$ ). At 21 days MTP flexion was not different between genotypes, however, at 28 days MTP Flexion was significantly increased in WT repairs relative to EP4cKO<sup>S100a4</sup> repairs ( $p = 0.03$ ) (Fig. 4A). A significant increase in Gliding Resistance occurred in WT repairs at day 14, relative to EP4cKO<sup>S100a4</sup> (WT:  $65.00 \pm 8.06$ ; EP4cKO<sup>S100a4</sup>:  $37.60 \pm 7.887$   $p = 0.034$ ) (Fig. 4B). No changes in Gliding Resistance were observed between groups at any other time-points.

#### EP4cKO<sup>S100a4</sup> does not impair mechanical properties during flexor tendon healing.

Max load at failure improved progressively in both WT and EP4cKO<sup>S100a4</sup> repairs from day 14 to day 28. While no differences were observed in max load at failure between genotypes at a given time point, accrual of strength was slightly retarded in EP4cKO<sup>S100a4</sup> repairs, and there was a trend toward decreased max load at failure in EP4cKO<sup>S100a4</sup>, relative to WT at Day 28 ( $p = 0.068$ ). The max load at failure improved 328% in WT repairs from day 14 to Day 28 (Day 14:  $0.83 \pm 0.09$ ; Day 28:  $3.57 \pm 0.62$ ). In contrast, EP4cKO<sup>S100a4</sup> repairs regained only 176% of max load at failure from day 14 to day 28 (Day 14:  $0.78 \pm 0.14$ ; Day 28:  $2.164 \pm 0.31$ ) (Fig. 4C). No differences in stiffness occurred between WT and EP4cKO<sup>S100a4</sup> repairs at any time, however, there was a trend toward an increase in stiffness in WT, relative to EP4cKO<sup>S100a4</sup> at day 28 (WT:  $0.739 \pm 0.07$ ; EP4cKO<sup>S100a4</sup>:  $0.399 \pm 0.16$ ,  $p = 0.076$ ) (Fig. 4D).

#### EP4cKO<sup>S100a4</sup> Repairs Heal with Decreased Expression of Col1a1 and Col3a1.

No change in *Colla1* expression was observed between groups at day 7 post-surgery, and the typical progressive increase in *Colla1* was observed in WT repairs between 7–21 days, followed by a return to baseline levels by day 28. In contrast, *Colla1* was significantly decreased in EP4cKO<sup>S100a4</sup> repairs at day 14 post-surgery relative to WT (WT:  $7.3 \pm 3.34$ ; EP4cKO<sup>S100a4</sup>:  $0.76 \pm 0.22$ ,  $p = 0.03$ ), followed by a non-significant decrease at day 21 (WT:  $10.36 \pm 5.11$ ; EP4cKO<sup>S100a4</sup>:  $5.20 \pm 1.52$ ,  $p = 0.1$ ) (Fig. 5A). Additionally, *Col3a1* increased transiently in WT repairs from day 7–14, followed by a gradual decline back to baseline levels by day 28. *Col3a1* expression was significantly decreased in EP4cKO<sup>S100a4</sup> repairs at day 14 relative to WT (WT:  $5.8 \pm 1.27$ ; EP4cKO<sup>S100a4</sup>:  $1.37 \pm 0.94$ ,  $p = 0.04$ ). No changes in *Col3a1* expression were observed between groups at 21 or 28 days post-surgery (Fig. 5B).



**Figure 5.** EP4cKO<sup>S100a4</sup> repairs heal with decreased expression of *Col1a1* and *Col3a1*. mRNA was isolated from EP4cKO<sup>S100a4</sup> and WT mice between 7–28 days post-surgery. A significant decrease in both (A) *Col1a1*, and (B) *Col3a1* expression was observed at day 14 post-surgery in EP4cKO<sup>S100a4</sup> relative to WT. Expression was normalized to the internal control  $\beta$ -actin. (\*) Indicates  $p < 0.05$ .

These data resulted in an elevated *Col1a1/Col3a1* ratio at 7 and 21 days post-surgery in WT repairs relative to EP4cKO<sup>S100a4</sup>.

**Loss of EP4 in Scleraxis-lineage cells does not alter flexor tendon healing.** The substantial increase in *EP4* expression in EP4cKO<sup>S100a4</sup> repairs suggests a cell population separate from *S100a4*-lineage expresses *EP4* during the later stages of healing. As a potential alternative population of *EP4* expressing cells, we examined the effects of *EP4* deletion in *Scleraxis*-lineage cells.


Tracing of *Scx*-lineage cells labels almost all resident tenocytes in the un-injured flexor tendon (green cells, Fig. 6A). Following injury there is an expansion of the *Scx*-lineage cells, with localization in both the native tendon and reactive epitenon, with very few *Scx*-lineage cells in the bridging scar tissue (Fig. 6B, Supplemental Fig. 2).

At day 14 post-repair no change in MTP flexion angle was observed between WT and EP4cKO<sup>Scx</sup> ( $p = 0.83$ , Fig. 6C). Consistent with this, no change in Gliding Resistance was observed between genotypes (Fig. 6D). Additionally, Max load at failure (WT:  $1.48 \text{ N} \pm 0.4$ ; EP4cKO<sup>Scx</sup>:  $0.97 \text{ N} \pm 0.15$ ,  $p = 0.17$ ) (Fig. 6E), and Stiffness ( $p = 0.75$ ) (Fig. 6F) were not altered by conditional deletion of *EP4* in *Scx*-lineage cells.

**$\alpha$ -SMA myofibroblasts are increased in EP4cKO<sup>S100a4</sup> repairs during later healing.** Given that adhesion formation increases during later healing in EP4cKO<sup>S100a4</sup> repairs we examined changes in pro-fibrotic, matrix producing myofibroblasts<sup>17</sup> as a potential mechanism of increased scar formation.  $\alpha$ -SMA expressing cells were observed in both the native tendon and scar tissue of WT repairs at day 21 (Fig. 7A, Supplemental Figs 3 and 4), and no difference in  $\alpha$ -SMA<sup>+</sup> cell area was observed between WT and EP4cKO<sup>S100a4</sup> repairs (Fig. 7C). However, abundant co-localization of  $\alpha$ -SMA and EP4 were observed in EP4cKO<sup>S100a4</sup> repairs at day 21 (yellow arrows, Fig. 7B, Supplemental Fig. 4), particularly in the scar tissue, with 9.5% of the cell area positive for both  $\alpha$ -SMA and EP4 (Fig. 7E). In contrast, very few double positive ( $\alpha$ -SMA<sup>+</sup>, EP4<sup>+</sup>) cells were observed in WT repairs (0.61%) (Fig. 7E), consistent with a decrease in EP4<sup>+</sup> cells at this time-point in WT (4.5%) relative to EP4cKO<sup>S100a4</sup> (29.8%,  $p = 0.0012$ ) (Fig. 7D). No further expression of EP4 was observed in the native tendon beyond the area immediately adjacent to the repair site (Fig. 7B).


## Discussion

In the present study we have examined the effects of deleting the PGE2 receptor, *EP4*, specifically in *S100a4*-lineage cells during flexor tendon healing. Given the strong association between inflammation and scar tissue formation<sup>18</sup>, we tested the hypothesis that loss of *EP4* in *S100a4*-lineage cells would decrease adhesion formation and improve tendon gliding function. Our data demonstrate that EP4cKO<sup>S100a4</sup> improves tendon gliding at 14 days post-surgery, consistent with a significant decrease in *EP4* expression prior to this point. Conversely, gliding function during the later stages of healing (day 28) is impaired, while *EP4* expression is similarly increased prior to these functional deficits. Taken together, these data suggests that early deletion of *EP4* in *S100a4*-lineage cells alters the kinetics of healing, potentially resulting in changes in the cellular milieu, and up-regulation of *EP4* by an alternative cell population during later healing. To determine the effects of *EP4* deletion in a different cell population, we examined healing in mice with *EP4* deletion in *Scleraxis*-lineage cells and found no effect on gliding function or mechanical properties. We then examined  $\alpha$ -SMA<sup>+</sup> myofibroblasts as potential cell mediator of increased *EP4* expression and adhesion formation during late healing in EP4cKO<sup>S100a4</sup> mice. A substantial increase in  $\alpha$ -SMA<sup>+</sup>, EP4<sup>+</sup> double-positive cells were observed in EP4cKO<sup>S100a4</sup>, suggesting that an influx of EP4-expressing  $\alpha$ -SMA<sup>+</sup> myofibroblasts may drive the up-regulation of EP4, potentially re-activating inflammation and promoting scar-mediated tendon healing.



**Figure 6.** EP4cKO<sup>Scx</sup> does not alter tendon healing. (A,B) Tracing of Scx-lineage cells using Scx-Cre; nT/nG demonstrates that Scx-lineage cells are present in the un-injured tendon (A), and the repaired tendon at day 14 post-surgery (B). Scale bar represents 100 microns. (C–F) Repaired tendons from EP4cKO<sup>Scx</sup> and WT mice were harvested at day 14 post-surgery. No changes in (C) MTP Flexion Angle, (D) Gliding Resistance, (E) Max load at failure, (F) Stiffness were observed between WT repairs and EP4cKO<sup>Scx</sup> repairs. For tensile testing, all repaired tendons failed at the suture site.

Immediately following tendon injury the acute inflammatory phase begins. While inflammation is necessary for the initiation and progression of the normal healing cascade, there is clear evidence that inflammation can also drive the scar tissue healing response in tendon. Embryonic<sup>19,20</sup> and early post-natal<sup>17</sup> healing are characterized by scarless, regenerative healing in contrast to healing in mature tissues which tend toward a scar tissue response. Changes in the inflammatory and immune environment have been proposed as a main factor in this differential response as the embryonic and early post-natal environment has an altered immune system, relative to adult<sup>21,22</sup>. Furthermore, MRL/MPJ mice, which have a blunted inflammatory response<sup>23</sup>, also demonstrate improved tendon healing<sup>24</sup>. Therefore, modulating inflammation represents a promising approach to improve tendon healing. Cox-2 inhibitors have shown promising inhibition of adhesion formation<sup>2,3</sup>, however systemic Cox-2 inhibitors are plagued by side-effects, including increased risk of adverse cardiovascular events, that must be given serious consideration<sup>25,26</sup>. Thus, we have focused on downstream targets of Cox-2 mediated inflammation, specifically the Prostaglandin E2 receptor, EP4. We have previously demonstrated that systemic antagonism of EP4 impaired gliding function during tendon healing. However, several studies have demonstrated the differential effects of



**Figure 7.** EP4-expressing  $\alpha$ -SMA myofibroblasts are increased in EP4cKO<sup>S100a4</sup> repairs during later healing. (A) Abundant expression of  $\alpha$ -SMA<sup>+</sup> was observed in EP4cKO<sup>S100a4</sup> and WT repairs on day 21 post-surgery.  $\alpha$ -SMA<sup>+</sup> cells are identified by red fluorescent staining, while nuclear stain DAPI is blue. Scale bars represent 200 microns. (B) Co-immunofluorescence for  $\alpha$ -SMA (red) and EP4 (green) demonstrate very few  $\alpha$ -SMA<sup>+</sup>, EP4<sup>+</sup> cells (yellow arrow) in WT repairs at day 21. In contrast, abundant  $\alpha$ -SMA<sup>+</sup>, EP4<sup>+</sup> cells (yellow arrows) are observed in EP4cKO<sup>S100a4</sup> repairs at this time. Scale bars represent 50 microns. (D–F) Quantitative assessment of (D)  $\alpha$ -SMA<sup>+</sup> cells, (E) EP4<sup>+</sup> cells, and (F)  $\alpha$ -SMA, EP4 double positive cells by immunofluorescence at day 21. (\*\*) Indicates  $p < 0.01$  between WT and EP4cKO<sup>S100a4</sup> repairs.

EP4 in a cell-type dependent context. Yokoyama *et al.*, demonstrated that pharmacological antagonism of EP4, or genetic knock-down of EP4 decreased abdominal aortic aneurysms<sup>27</sup>. However, Tang *et al.*, demonstrate that bone marrow cell-specific deletion of EP4 promotes abdominal aortic aneurysms<sup>12</sup>. Taken together these data support investigating cell-type specific effects of EP4 deletion on tendon healing.

The differential effects of systemic versus cell-type specific EP4 inhibition are demonstrated by alterations in ECM gene expression. EP4 antagonist treatment resulted in earlier expression of *Col3a1*, relative to vehicle treated repairs<sup>10</sup>, suggesting that systemic EP4 antagonism promotes an accelerated shift toward scar-mediated healing. In contrast, *Col3a1* was significantly decreased in EP4cKO<sup>S100a4</sup> repairs, relative to WT repairs, consistent with improved gliding in EP4cKO<sup>S100a4</sup> repairs at that time-point. However, expression of *Coll1a1*, which is associated with restoration of native tendon composition, is also decreased in EP4cKO<sup>S100a4</sup> repairs throughout

healing, suggesting that EP4cKO<sup>S100a4</sup> disrupts the normal progression of tendon healing. Based on gliding function, mechanics and gene expression data, WT repairs progress through the normal phases of healing, with progressive acquisition of mechanical properties, a transient decrease in gliding function, and a shift from early *Col3a1* expression to *Col1a1*. In contrast, no change in gliding function is observed over the course of healing in EP4cKO<sup>S100a4</sup>, and diminished acquisition of mechanical properties occurs; max load at failure increases 102% in WT repairs from day 21 to day 28, compared to a 1.6% increase in max load over the same time-period in EP4cKO<sup>S100a4</sup> repairs. Indeed, following an early failure to form adhesions, EP4cKO<sup>S100a4</sup> repairs seem to remain relatively static, as no change in GR or MTP Flexion angle is observed over time, and no up-regulation of *Col3a1* or *Col1a1* is observed. Taken together, these data may suggest that early deletion of *EP4* in *S100a4*-lineage cells halts progression through the normal phases of tendon healing.

Given the differences in healing between EP4 antagonist treated mice, and EP4cKO<sup>S100a4</sup> mice, we examined the effects of EP4 conditional deletion in *Scleraxis*-lineage cells. *Scleraxis* is required for normal tendon formation<sup>28</sup>, and is expressed by resident tenocytes in mature tendon<sup>17</sup>. Recently, *Scx*-lineage cells have been shown to participate in regenerative tendon healing in neonates, with minimal involvement of *Scx*<sup>+</sup> cells in mature, scar mediated healing<sup>17</sup>, which may account for the lack of phenotype observed in EP4cKO<sup>Scx</sup>. Furthermore, while *Scx*-lineage cells are observed in the healing tendon (Fig. 6), we have used a non-inducible *Scx*-Cre, so it is unknown if these *Scx*-lineage<sup>+</sup> cells are residual cells from development, or newly activated *Scx*-expressing cells that are involved in healing.

Myofibroblasts are believed to be the cellular drivers of fibrotic tendon healing and peritendinous adhesions<sup>29,30</sup>, given their ability to produce abundant collagenous ECM. We have used  $\alpha$ -SMA expression to identify myofibroblasts, consistent with many other studies<sup>31–33</sup>. However,  $\alpha$ -SMA has also been used to mark mesenchymal progenitors<sup>34</sup>. While future studies will clarify the lineage, fate and function of these cells during tendon healing, there is a consistent demonstration of the involvement of  $\alpha$ -SMA<sup>+</sup> cells during tendon healing. While our data suggest that  $\alpha$ -SMA<sup>+</sup> myofibroblasts drive the up-regulation of EP4 that occurs during later healing in EP4cKO<sup>S100a4</sup>, it is not clear if the increase is driven by elevated levels of the EP4 ligand PGE2, and which cells are producing PGE2 at this stage in healing. Macrophages play important roles in both initiation and resolution of inflammation, and have been shown to produce PGE2<sup>35</sup>. However, PGE2 can also alter macrophage polarization<sup>36,37</sup>, and recent work by Fernando *et al.*, demonstrate that myofibroblast-derived PGE2 can promote alternative activation of macrophages<sup>38</sup>. Thus, understanding the relationship between myofibroblasts, macrophages and PGE2/EP4 signaling during tendon healing will be an important area of future research.

While these data clearly identify different cell-type specific functions of EP4 in tendon healing there are several limitations that must be considered. We have examined the effects of EP4cKO<sup>Scx</sup> at only one time-point during healing, however, if EP4cKO<sup>Scx</sup> were to alter healing, our previous data would suggest these effects would occur prior to day 14 based on the expression profile of *Scx* in this healing model<sup>39</sup>. We have also not examined the long-term mechanical effects of EP4cKO<sup>S100a4</sup> on tendon healing. In addition, the actual identity of *S100a4*<sup>+</sup> cells is both unclear and controversial. Osterreicher *et al.*, have identified *S100a4*<sup>+</sup> cells as a sub-population of inflammatory macrophages<sup>40</sup>, while Nishitani *et al.*, identified *S100a4*<sup>+</sup> cells as myofibroblasts<sup>41</sup>. Thus, future studies to more clearly define the origin, fate and function of *S100a4* during tendon healing are needed. In addition, we have not examined the role of other EP receptors in EP4cKO<sup>S100a4</sup> repairs, which will be an important consideration in future studies, given that loss of EP2 is associated with fibrotic progression in the lung ability of EP2 in particular to also promote fibrosis<sup>42,43</sup>. While these data suggest a role for  $\alpha$ -SMA<sup>+</sup> cell-mediated EP4 induction, and increased scar formation, conditional deletion studies of EP4 using an  $\alpha$ -SMA-Cre mouse would be required to definitively identify the role of *EP4* in  $\alpha$ -SMA-lineage cells. Finally, the release of the FDL tendon at the proximal myotendinous junction (MTJ) decreases strain on the repair to protect the repair site, however, this is likely to alter healing. However, some restoration of the MTJ is observed during healing, although we have not measured this strain experimentally, and therefore do not know what the effects of this release or restoration of the MTJ are on healing.

Together with our previous studies using an EP4 systemic antagonist, these data demonstrate cell-type specific functions of EP4 in scar-mediated tendon healing. Our data suggest that deletion of EP4 in *S100a4*-lineage cells inhibits range of motion-limiting scar tissue without further compromising mechanical properties. However, these beneficial effects of EP4cKO<sup>S100a4</sup> are transient, with aberrant up-regulation of EP4 during later healing, mediated at least in part by  $\alpha$ -SMA<sup>+</sup> cells, and a subsequent decrease in range of motion. These data suggest that sustained inhibition of EP4 in *S100a4*-lineage cells, and  $\alpha$ -SMA-lineage cells may result in prolonged improvements in tendon healing. Furthermore, understanding the mechanisms through which EP4 promotes scar-mediated healing will identify novel therapeutic targets to improve tendon healing.

## Methods

**Animal Ethics.** This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All animal procedures were approved by the University Committee on Animal Research (UCAR) at the University of Rochester (UCAR Number: 2014-004).

**Mice.** The following strains were obtained from Jackson Laboratories (Bar Harbor, ME): *EP4*<sup>fllox/fllox</sup> (#28102), *ROSA*<sup>nT/nG</sup> (#23035) *s100a4*-Cre (#12641). The *S100a4*-Cre<sup>44</sup> mice were generated on a BALB/cByJ background and were back-crossed to C56Bl/6 J for at least 10 generations prior to crossing to *EP4*<sup>fllox/fllox</sup> or *ROSA*<sup>nT/nG</sup> strains. *Scx*-Cre mice were generously provided by Dr. Ronen Schweitzer. Conditional knock-out animals were generated as homozygotes (Cre<sup>+</sup>; *EP4*<sup>fllox/fllox</sup>), Cre<sup>-</sup>; *EP4*<sup>fllox/fllox</sup> littermates were used as wildtype (WT). The *ROSA*<sup>nT/nG</sup> construct is a dual reporter in which all cells express nuclear Tomato red (nT) fluorescence in the absence of Cre-mediated recombination, and nuclear GFP (nG) upon Cre-mediated recombination.



**Flexor Tendon Surgery.** At 10–12 weeks of age mice underwent complete transection and repair of the flexor digitorum longus (FDL) tendon in the right hind-paw as previously described<sup>39,45</sup>. Briefly, mice were anesthetized with Ketamine (60 mg/kg) and Xylazine (4 mg/kg). A pre-surgical dose of Buprenorphine (0.05 mg/kg) was administered followed by further analgesia every 12-hours after surgery as needed. Following preparation of the surgical site, the FDL was surgically transected in the transverse plane at the myotendinous junction in the calf to protect the repair site from high strains. The skin was closed with a single 5-0 suture. A 1-2 cm incision was then made on the posterior surface of the hindpaw, soft tissue was retracted to identify the FDL, and the FDL was completely transected using micro-scissors. Following transection the FDL was repaired using 8-0 nylon sutures (Ethicon, Somerville, NJ) in a modified Kessler pattern. The skin was closed with 5-0 suture. The animals were allowed unrestricted weight-bearing and movement, and had *ad-libitum* access to food and water.

**RNA extraction and qPCR.** Total RNA was extracted from healing tendons between 3–28 days post-surgery. RNA was extracted from the repair site and 1-2 mm of native tendon on both sides of the repair. RNA was extracted from 3 repairs per genotype per time-point. RNA was extracted using TRIzol reagent (Life Technologies). 500ng of RNA was used for reverse transcription of cDNA using iScript cDNA synthesis kit (Bio-Rad, Hercules, CA). Quantitative PCR (qPCR) was then run using cDNA and gene specific primers (Supplemental Table 1). Expression was normalized to expression in day 3 WT repairs, and the internal control  $\beta$ -actin. Expression was normalized to day 3 repairs because the expression levels of most genes of interest are extremely low, or un-detectable in un-operated mice, likely due to the quiescent nature of these cells. Normalization to day 3 allows a more direct comparison of changes in gene expression changes during the healing process. All qPCR was run in triplicate and repeated at least twice.

**Histology- Frozen Sectioning.** Following sacrifice the hind limbs of *S100a4-Cre<sup>+</sup>*; *ROSA<sup>nT/nG</sup>* and *Scx-Cre*; *ROSA<sup>nT/nG</sup>* mice were removed at the mid-tibia, and skin and excess soft tissue was removed. The skin on the sole of the foot remained intact so as not to disturb the repair site. Tissues were fixed in 10% neutral buffered formalin for 24 hrs at 4 °C, decalcified in 14% EDTA (pH 7.2-7.4) for 4 days at 4 °C, and processed in 30% sucrose (in PBS) for 24 hours prior to embedding in Cryomatrix (ThermoFisher, Waltham, MA). Eight-micron serial sagittal sections were cut using a cryotape-transfer method<sup>46</sup>. Sections were affixed to glass slides using 1% chitosan in 0.25% acetic acid, dried overnight at 4 °C, and coverslipped using Fluoromount aqueous mounting medium (F46802, Sigma, St. Louis, MO). Following fluorescent imaging, coverslips were gently removed in PBS, and slides were stained with Hematoxylin & Eosin, followed by dehydration and coverslipping. Both fluorescent and brightfield imaging was done on a VS120 Virtual Slide Microscope (Olympus, Waltham, MA). Images are representative of at least three specimens per time-point.

**Histology- Paraffin sectioning.** Hind limbs were removed as above and fixed for 72hrs in 10% NBF at room temperature. Specimens were then decalcified for 14 days in 14% EDTA (pH 7.2–7.4), processed and embedded in paraffin. Three-micron serial sagittal sections were cut, de-waxed, rehydrated, and probed with antibodies for EP4 (1:100, #sc-16022, Santa Cruz Biotechnology, Dallas, TX) and  $\alpha$ -SMA-Cy3 (1:200, #C6198, Sigma, St. Louis, MO) overnight at 4 °C. An AlexaFluor 488 secondary antibody was used with EP4 (1:200, #705-546-147, Jackson ImmunoResearch, West Grove, PA). The nuclear counterstain DAPI was used, and fluorescence was imaged with a VS120 Virtual Slide Microscope (Olympus, Waltham, MA). Following imaging, coverslips were removed by immersing slides in PBS, and then slides were stained with Hematoxylin & Eosin (H&E).

**Quantification of fluorescence.** Digital fluorescent images obtained from the slide scanner were processed using Visiopharm image analysis software v.6.7.0.2590 (Visiopharm, Hørsholm, Denmark) Automatic segmentation was done using the threshold classifier to define cell populations based on fluorescent channel. A double constraint was defined to determine co-localization of EP4 and  $\alpha$ -SMA staining. Regions of interest were drawn to include only the scar tissue area for processing. To improve accuracy of quantification, manual correction was done to exclude sutures/blood vessels, and a post-processing step was added to ignore any debris smaller than 10  $\mu\text{m}^2$ . The area of each fluorescent signal was calculated, and these values were used to determine overall percentage of each cell type or stain present in the scar tissue.

**Assessment of Gliding Function.** Following sacrifice the hindlimb was removed at the knee, and skin was removed down to the ankle. The FDL was isolated proximally near the original myotendinous junction and secured using cyanoacrylate between two pieces of tape as previously described<sup>39,47</sup>. Briefly, the tibia was secured in an alligator clip and the tendon was incrementally loaded with small weights from 0–19g; digital images were taken at each load. The flexion angle of the metatarsophalangeal (MTP) joint was measured from the digital images. The MTP Flexion angle corresponds to the degrees of flexion upon application of the 19 g weight. Un-injured tendons undergo complete flexion of the digits at 19 g. Gliding resistance was based on the changes in MTP flexion angle of the range of applied loads with higher gliding resistance indicative of impaired gliding function and adhesion formation. Eight-10 specimens per genotype per time-point were analyzed for gliding function.

**Biomechanical testing.** Following Gliding testing, the tibia was removed at the ankle and the toes and proximal section of the FDL in the tape were secured in opposing ends of a custom grips<sup>39,47</sup> on an Instron 8841 DynaMight™ axial servohydraulic testing system (Instron Corporation, Norwood, MA). The tendons were tested in tension at a rate of 30mm/minute until failure. Maximum load at failure was automatically logged, while stiffness was calculated at the slope of the linear region of the force-displacement curve. Eight-10 specimens per genotype per time-point underwent mechanical testing. Biomechanical testing was not conducted on earlier

time-points due to the fragility of the samples and because our previous studies<sup>39</sup> have demonstrated that the observed max load at failure at early time-points is entirely due to the sutures and not the healing tissue.

**Statistical analyses.** Quantitative data are presented at mean  $\pm$  standard error of the mean (SEM). A two-way analysis of variance (ANOVA) with Bonferroni's multiple comparisons test was used to analyze qPCR, biomechanical and gliding data of WT and EP4cKO<sup>S100a4</sup> tendon repairs over time. A one-way ANOVA with Bonferroni's multiple comparisons test was used to analyze nGFP<sup>+</sup> quantification. A t-test was used to analyze biomechanical and gliding data from un-injured tendons, EP4cKO<sup>S100a4</sup> vs. WT repairs at day 14, and quantification of immunofluorescence.

**Data Availability Statement.** All data generated or analysed during this study are included in this article.

## References

- Feldscher, S. B. & Schneider, L. H. Flexor tenolysis. *Hand Surg* **7**, 61–74 (2002).
- Virchenko, O., Skoglund, B. & Aspenberg, P. Parecoxib impairs early tendon repair but improves later remodeling. *Am J Sports Med* **32**, 1743–1747 (2004).
- Rouhani, A., Tabrizi, A. & Ghavidel, E. Effects of non-steroidal anti-inflammatory drugs on flexor tendon rehabilitation after repair. *Arch Bone Jt Surg* **1**, 28–30 (2013).
- Khan, M. H., Li, Z. & Wang, J. H. Repeated exposure of tendon to prostaglandin-E2 leads to localized tendon degeneration. *Clin J Sport Med* **15**, 27–33 (2005).
- Koshima, H. *et al.* Expression of interleukin-1beta, cyclooxygenase-2, and prostaglandin E2 in a rotator cuff tear in rabbits. *J Orthop Res* **25**, 92–97 (2007).
- Li, Z. *et al.* Inflammatory response of human tendon fibroblasts to cyclic mechanical stretching. *Am J Sports Med* **32**, 435–440, doi:10.1177/0095399703258680 (2004).
- Wang, J. H., Li, Z., Yang, G. & Khan, M. Repetitively stretched tendon fibroblasts produce inflammatory mediators. *Clin Orthop Relat Res*, 243–250 (2004).
- Zhang, J. & Wang, J. H. Production of PGE(2) increases in tendons subjected to repetitive mechanical loading and induces differentiation of tendon stem cells into non-tenocytes. *J Orthop Res* **28**, 198–203, doi:10.1002/jor.20962 (2010).
- Thampatty, B. P., Li, H., Im, H. J. & Wang, J. H. EP4 receptor regulates collagen type-I, MMP-1, and MMP-3 gene expression in human tendon fibroblasts in response to IL-1 beta treatment. *Gene* **386**, 154–161 (2007).
- Geary, M. B. *et al.* Systemic EP4 Inhibition Increases Adhesion Formation in a Murine Model of Flexor Tendon Repair. *PLoS one* **10**, e0136351, doi:10.1371/journal.pone.0136351 (2015).
- Yokoyama, U. *et al.* Inhibition of EP4 signaling attenuates aortic aneurysm formation. *PLoS one* **7**, e36724, doi:10.1371/journal.pone.0036724 (2012).
- Tang, E. H. *et al.* Deletion of EP4 on bone marrow-derived cells enhances inflammation and angiotensin II-induced abdominal aortic aneurysm formation. *Arterioscler Thromb Vasc Biol* **31**, 261–269, doi:10.1161/ATVBAHA.110.216580 (2011).
- Chen, L. *et al.* S100A4 promotes liver fibrosis via activation of hepatic stellate cells. *J Hepatol* **62**, 156–164, doi:10.1016/j.jhep.2014.07.035 (2015).
- Louka, M. L. & Ramzy, M. M. Involvement of fibroblast-specific protein 1 (S100A4) and matrix metalloproteinase-13 (MMP-13) in CCl4-induced reversible liver fibrosis. *Gene* **579**, 29–33, doi:10.1016/j.gene.2015.12.042 (2016).
- Lawson, W. E. *et al.* Characterization of fibroblast-specific protein 1 in pulmonary fibrosis. *Am J Respir Crit Care Med* **171**, 899–907, doi:10.1164/rccm.200311-1535OC (2005).
- Tamaki, Y. *et al.* Metastasis-associated protein, S100A4 mediates cardiac fibrosis potentially through the modulation of p53 in cardiac fibroblasts. *J Mol Cell Cardiol* **57**, 72–81, doi:10.1016/j.yjmcc.2013.01.007 (2013).
- Howell, K. *et al.* Novel Model of Tendon Regeneration Reveals Distinct Cell Mechanisms Underlying Regenerative and Fibrotic Tendon Healing. *Sci Rep* **7**, 45238, doi:10.1038/srep45238 (2017).
- Galatz, L. M., Gerstenfeld, L., Heber-Katz, E. & Rodeo, S. A. Tendon regeneration and scar formation: The concept of scarless healing. *J Orthop Res* **33**, 823–831, doi:10.1002/jor.22853 (2015).
- Beredjikian, P. K. *et al.* Regenerative versus reparative healing in tendon: a study of biomechanical and histological properties in fetal sheep. *Annals of biomedical engineering* **31**, 1143–1152 (2003).
- Favata, M. *et al.* Regenerative properties of fetal sheep tendon are not adversely affected by transplantation into an adult environment. *J Orthop Res* **24**, 2124–2132 (2006).
- Sattler, S. & Rosenthal, N. The neonate versus adult mammalian immune system in cardiac repair and regeneration. *Biochim Biophys Acta* **1863**, 1813–1821, doi:10.1016/j.bbamcr.2016.01.011 (2016).
- Simon, A. K., Hollander, G. A. & McMichael, A. Evolution of the immune system in humans from infancy to old age. *Proc Biol Sci* **282**, 20143085, doi:10.1098/rspb.2014.3085 (2015).
- Ueno, M. *et al.* Accelerated wound healing of alkali-burned corneas in MRL mice is associated with a reduced inflammatory signature. *Invest Ophthalmol Vis Sci* **46**, 4097–4106, doi:10.1167/iovs.05-0548 (2005).
- Lalley, A. L. *et al.* Improved biomechanical and biological outcomes in the MRL/MpJ murine strain following a full-length patellar tendon injury. *J Orthop Res* **33**, 1693–1703, doi:10.1002/jor.22928 (2015).
- Olsen, A. M. *et al.* Long-term cardiovascular risk of nonsteroidal anti-inflammatory drug use according to time passed after first-time myocardial infarction: a nationwide cohort study. *Circulation* **126**, 1955–1963, doi:10.1161/CIRCULATIONAHA.112.112607 (2012).
- Antman, E. M. *et al.* Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. *Circulation* **115**, 1634–1642, doi:10.1161/CIRCULATIONAHA.106.181424 (2007).
- Aoki, N. *et al.* Adipocyte-derived microvesicles are associated with multiple angiogenic factors and induce angiogenesis *in vivo* and *in vitro*. *Endocrinology* **151**, 2567–2576, doi:10.1210/en.2009-1023 (2010).
- Murchison, N. D. *et al.* Regulation of tendon differentiation by scleraxis distinguishes force-transmitting tendons from muscle-anchoring tendons. *Development* (2007).
- Kvist, M., Jozsa, L., Jarvinen, M. & Kvist, H. Fine structural alterations in chronic Achilles paratenonitis in athletes. *Pathol Res Pract* **180**, 416–423, doi:10.1016/S0344-0338(85)80115-1 (1985).
- Jarvinen, M. *et al.* Histopathological findings in chronic tendon disorders. *Scand J Med Sci Sports* **7**, 86–95 (1997).
- Li, B. & Wang, J. H. Fibroblasts and myofibroblasts in wound healing: force generation and measurement. *J Tissue Viability* **20**, 108–120, doi:10.1016/j.jtv.2009.11.004 (2011).
- Hinz, B., Gabbiani, G. & Chaponnier, C. The NH2-terminal peptide of alpha-smooth muscle actin inhibits force generation by the myofibroblast *in vitro* and *in vivo*. *J Cell Biol* **157**, 657–663, doi:10.1083/jcb.200201049 (2002).
- Cadby, J. A., Buehler, E., Godbout, C., van Weeren, P. R. & Snedeker, J. G. Differences between the cell populations from the peritenon and the tendon core with regard to their potential implication in tendon repair. *PLoS one* **9**, e92474, doi:10.1371/journal.pone.0092474 (2014).

34. Dymont, N. A. *et al.* Lineage tracing of resident tendon progenitor cells during growth and natural healing. *PLoS one* **9**, e96113, doi:10.1371/journal.pone.0096113 (2014).
35. Kuroda, E. & Yamashita, U. Mechanisms of enhanced macrophage-mediated prostaglandin E2 production and its suppressive role in Th1 activation in Th2-dominant BALB/c mice. *J Immunol* **170**, 757–764 (2003).
36. Luan, B. *et al.* CREB pathway links PGE2 signaling with macrophage polarization. *Proc Natl Acad Sci USA* **112**, 15642–15647, doi:10.1073/pnas.1519644112 (2015).
37. MacKenzie, K. F. *et al.* PGE(2) induces macrophage IL-10 production and a regulatory-like phenotype via a protein kinase A-SIK-CRTC3 pathway. *J Immunol* **190**, 565–577, doi:10.4049/jimmunol.1202462 (2013).
38. Fernando, M. R., Giembycz, M. A. & McKay, D. M. Bidirectional crosstalk via IL-6, PGE2 and PGD2 between murine myofibroblasts and alternatively activated macrophages enhances anti-inflammatory phenotype in both cells. *British journal of pharmacology* **173**, 899–912, doi:10.1111/bph.13409 (2016).
39. Loiselle, A. E. *et al.* Remodeling of murine intrasynovial tendon adhesions following injury: MMP and neotendon gene expression. *J Orthop Res* **27**, 833–840, doi:10.1002/jor.20769 (2009).
40. Osterreicher, C. H. *et al.* Fibroblast-specific protein 1 identifies an inflammatory subpopulation of macrophages in the liver. *Proc Natl Acad Sci USA* **108**, 308–313, doi:10.1073/pnas.1017547108 (2011).
41. Nishitani, Y. *et al.* Fibroblast-specific protein 1 is a specific prognostic marker for renal survival in patients with IgAN. *Kidney international* **68**, 1078–1085, doi:10.1111/j.1523-1755.2005.00500.x (2005).
42. Moore, B. B. *et al.* Bleomycin-induced E prostanoind receptor changes alter fibroblast responses to prostaglandin E2. *J Immunol* **174**, 5644–5649 (2005).
43. Huang, S. K. *et al.* Variable prostaglandin E2 resistance in fibroblasts from patients with usual interstitial pneumonia. *Am J Respir Crit Care Med* **177**, 66–74, doi:10.1164/rccm.200706-963OC (2008).
44. Bhowmick, N. A. *et al.* TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. *Science* **303**, 848–851 (2004).
45. Ackerman, J. E. & Loiselle, A. E. Murine Flexor Tendon Injury and Repair Surgery. *J Vis Exp*. doi:10.3791/54433 (2016).
46. Dymont, N. A. *et al.* High-Throughput, Multi-Image Cryohistology of Mineralized Tissues. *J Vis Exp*. doi:10.3791/54468 (2016).
47. Hasslund, S. *et al.* Adhesions in a murine flexor tendon graft model: Autograft versus allograft reconstruction. *J Orthop Res* **26**, 824–833 (2008).

## Acknowledgements

We would like to thank the Histology, Biochemistry and Molecular Biology (HBMI) and Biomechanics, Biomaterials and Multi-modal Tissue Engineering (BBMTI) Cores in the Center for Musculoskeletal Research (CMSR) at the University of Rochester for technical assistance with histology and biomechanical testing, respectively. This work was supported in part by NIH/NIAMS 1K01AR068386-01 (to AEL), and R01 AR056696. The HBMI and BMTI Cores were supported in part by NIH/ NIAMS P30 AR069655.

## Author Contributions

Study conception and design: R.J.O., A.E.L.; Acquisition of data: J.E.A., K.T.B.; Analysis and interpretation of data: J.E.A., K.T.B., A.E.L.; Drafting of manuscript: J.E.A., A.E.L.; Revision and approval of manuscript: J.E.A., K.T.B., R.J.O., A.E.L.

## Additional Information

**Supplementary information** accompanies this paper at doi:10.1038/s41598-017-09407-7

**Competing Interests:** The authors declare that they have no competing interests.

**Publisher's note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2017